Lantern Pharma (NasdaqCM:LTRN) Update / Briefing November 20, 2025 04:30 PM ET Speaker1Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar. We'll be talking in depth today with some of our Lantern Pharma team and also with our collaborator and partner in developing the trial and some of the early science behind LP-184. Dr. Igor Astsaturov from Fox Chase is also on with us as well. I'm going to be talking about, overall, the drug, just to give everyone an overview of ...

MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2025. Key highlights include: (CAD)Q3 2025% Change vs.Q3 2024YTD 2025% Change vs.YTD 2024Trailing Twelve Months (TTM) Sept 30, 2025% Change vs.TTM Sept 30, 2024Canadian Pharma Sales9,864,254+19%28,351,130+16%<td style="border-right: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-ali ...

Core Points - BioSyent Inc. has declared a quarterly dividend of $0.05 per common share, payable on December 15, 2025, to shareholders of record on November 28, 2025 [1] - The dividend for the fourth quarter of 2025 is consistent with the third quarter of 2025, indicating stable dividend policy [1] - The dividend qualifies as an 'eligible dividend' for Canadian income tax purposes [1] Company Overview - BioSyent Inc. is a profitable growth-oriented specialty pharmaceutical company listed on the TSX Venture Exchange under the symbol "RX" [2] - The company focuses on in-licensing or acquiring innovative pharmaceutical and healthcare products that are safe, effective, and have a proven track record [2] - BioSyent markets its products through community, specialty, and international business units to support healthcare professionals [2] Share Information - As of the date of the press release, BioSyent has 11,262,282 common shares outstanding [3]

Core Insights - Seeking Alpha welcomes a new contributing analyst, Joseph Elijah, who aims to share investment ideas and insights with serious investors [1] Group 1: Analyst Background - The new analyst has over a decade of experience in quantitative finance, risk management, and derivatives trading across global financial markets [2] - The analyst holds a Master's degree in Quantitative Finance from the Wharton School and began their career at Morgan Stanley, focusing on model risk management [2] - After five years at Morgan Stanley, the analyst worked at DRW for six years, initially as a Business Analyst in FICC Options and later as a Quantitative Researcher in Israel [2] Group 2: Investment Philosophy - The analyst has transitioned to managing a personal investment portfolio and aims to share knowledge and investment philosophy online [2] - Seeking Alpha is identified as the preferred platform for connecting with serious investors who value in-depth analysis [2]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

PresentationSloan SimpsonGlobal Head of Investor Relations All right. Hello, everyone and welcome to our 2025 Meet Novartis Management Investor Event. Thank you, as always, for your time, interest and engagement with us. This is a special event, which we've been doing for over 10 years because it allows investors and analysts to interact with our management teams in an open Q&A format. Today we'll start with a presentation and a Q&A by Vas, followed by breakout sessions with our core therapeutic areas and c ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The last time I posted on Gilead Sciences, Inc. ( GILD ), the California-based Pharma giant, and a company I am invested in, it was to cover its Q1 2025 earnings andEdmund Ingham is a biotech consultant. He has bee ...

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLXNovember 20, 2025 4:29 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusiv ...

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Inhibikase intend ...